DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Betadex is an investigational drug.
There have been 8 clinical trials for Betadex. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Schizophrenia, Psychomotor Agitation, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Bayer, Janssen Sciences Ireland UC, and Yang Fude.
There are two US patents protecting this investigational drug and thirty international patents.
Recent Clinical Trials for Betadex
|Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440||Janssen Research & Development, LLC||Phase 1|
|A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe||Janssen Sciences Ireland UC||Phase 1|
|The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation||Pfizer||Phase 4|
Top disease conditions for Betadex
Top clinical trial sponsors for Betadex
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Betadex||See Pricing||Antifungal compound process||Mycovia Pharmaceuticals, Inc. (Durham, NC) U.S. Department of Health and Human Services (Washington, DC)||See Pricing|
|Betadex||See Pricing||Therapeutic and imaging compositions and uses thereof||Purdue Research Foundation (West Lafayette, IN)||See Pricing|
|Betadex||See Pricing||Hard coating composition||LG CHEM, LTD. (Seoul, KR)||See Pricing|
|Betadex||See Pricing||Therapeutic nuclease compositions and methods||University of Washington (Seattle, WA)||See Pricing|
|Betadex||See Pricing||Pharmaceutical composition for preventing or treating skin cancer comprising Panax spp. plant extract and method of preventing or treating skin cancer in a subject using the same||KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (Seoul, KR)||See Pricing|
|Betadex||See Pricing||Nanospheres encapsulating bioactive material and method for formulation of nanospheres||THE CORPORATION OF MERCER UNIVERSITY (Macon, GA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Betadex||European Patent Office||3119755||2034-03-19||See Pricing|
|Betadex||World Intellectual Property Organization (WIPO)||2015143180||2034-03-19||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|